Differentiation of herpes simplex virus types 1 and 2 by sensitivity to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Selective inhibition of herpes simplex virus (HSV) type 1 replication but not of HSV type 2 replication by (E)-5-(2-bromovinyl)2'-deoxyuridine (BVDU) was utilized to differentiate clinical isolates of these viruses. BVDU (0.7 microgram/ml) reduced HSV type 1 PFU by an average of 2.74 log10, but had no effect on the plaque-forming ability of HSV type 2 isolates. The incorporation of BVDU into the media of primary cell cultures used for virus isolation in the clinical laboratory allowed for the correct presumptive identification of HSV types.
D000818:Animals; D001973:Bromodeoxyuridine / Q000031:analogs & derivatives* / Q000494:pharmacology; D002478:Cells, Cultured; D002642:Chick Embryo; D003470:Culture Media; D006168:Guinea Pigs; D018139:Simplexvirus / Q000145:classification* / Q000187:drug effects / Q000254:growth & development; D010948:Viral Plaque Assay; D014779:Virus Replication / Q000187:drug effects
D003470:Culture Media; C020235:brivudine; D001973:Bromodeoxyuridine